OrbiMed Advisors was established in 1989 by Samuel Isaly. At Chase Manhattan Bank, Merrill Lynch, Legg Mason and S.G. Warburg, he worked as a pharmaceutical analyst. For 22 years, Isaly served as the Worldwide Healthcare Trust Plc’s portfolio manager. The top 10 holdings of OrbiMed Advisors’ 13F public stock portfolio were concentrated at 29.71 percent, valued at $9.10 billion. More than $20.09 million is invested in Gilead Sciences Inc. by hedge fund manager Samuel Isaly. An increase in the hedge fund’s stake in the business of 248 percent was recorded in the third quarter of the year 2021. More than $66.28 million worth of Biogen Inc. shares are held by OrbiMed Advisors. Biogen’s price target has been reduced from $390 to $335 by Canaccord Genuity.
Here is the list of Insider Monkey’s top 10 stock picks of Samuel Isaly’s OrbiMed Advisors. After an upgrade to “Buy,” Jefferies analyst Michael Yee cut his rating on Adagio Therapeutics, Inc. in December. Shares worth $227.40 million have been purchased by Samuel Isaly’s hedge fund. Biopharmaceutical company Edgewise Therapeutics, Inc. focuses on the development and commercialization of novel medicines for severe, uncommon, and unmet medical needs in the field of muscular disease. During the third quarter of fiscal 2021, the company reported a loss of $0.26 per share. In November, BMO Capital analyst Evan Seigerman began covering Mirati Therapeutics, Inc. and rated it as “Outperform,” with a price target of $187. Compared to the same period last year, revenue increased by 529.8 percent. Company: Boston Scientific Corporation is a medical device manufacturer and marketer specializing in interventional medicine. In the first quarter of 2021, OrbiMed Advisors began building its stake in Ikena Oncology, Inc., and it now owns 11.90 million shares, valued at $255.95 million as of the third quarter of 2021. The stock accounts for 2.81 percent of the 13F portfolio of the hedge fund. For more details, click Top 10 Stock Picks Of Samuel Isaly’s Orbimed Advisors.
